| Literature DB >> 18089865 |
Peter Grimison1, Peter Galettis, Susan Manners, Maria Jelinek, Ekkaphon Metharom, Paul L de Souza, Winston Liauw, Matthew J Links.
Abstract
PURPOSE: Controversy exists over the optimal dose rate for administration of gemcitabine. There is a strong pharmacologic rationale for increased intracellular accumulation with prolonged infusions, but this failed to translate into a significant benefit in a large randomized study. The purpose of this study was to compare the intracellular pharmacokinetics of gemcitabine given for 30 minutes or for 100 minutes in a crossover design. PATIENTS AND METHODS: We randomly assigned 33 patients to a standard dose of 1,000 mg/m2 over either 30 minutes or 100 minutes. At the second week, they were transferred to the alternate schedule. Blood samples were collected at various times after the gemcitabine infusion. Gemcitabine and difluorodeoxyuridine were measured in plasma by high-performance liquid chromatography (HPLC), and gemcitabine-triphosphate was measured by HPLC in leukocytes.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18089865 DOI: 10.1200/JCO.2007.10.7078
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544